Author

Amanda Putri Rahmadian

Observed names: A. Putri Rahmadian, Amanda P. Rahmadian, Amanda Rahmadian

Institution: Rotman Research Institute

Observed institutions: Sunnybrook Health Science Centre, University of Waterloo, Sunnybrook Hospital, Sunnybrook Research Institute, Baycrest Academy for Research and Education, Rotman Research Institute, Odette Cancer Centre

ORCID: 0000-0002-5367-0820

Observed ORCID: 0000-0002-5367-0820

OpenAlex ID: A5081791634

Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life

2021 · Vanessa Arciero, Seanthel Delos Santos, et al. · JAMA Network Open · 44

Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis

2019 · Ambica Parmar, Jorge Chaves-Porras, et al. · Critical Reviews in Oncology/Hematology · 29

Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time

2020 · Amanda Putri Rahmadian, Seanthel Delos Santos, et al. · Journal of the National Comprehensive Cancer Network · 22

Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis

2022 · Suji Udayakumar, Ambica Parmar, et al. · Critical Reviews in Oncology/Hematology · 16

Evaluation of the impact of patient involvement in health technology assessments: A scoping review

2020 · Robert J. Mason, Karlee M. Searle, et al. · International Journal of Technology Assessment in Health Care · 14

Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework

2021 · Seanthel Delos Santos, Noah Witzke, et al. · Journal of the National Comprehensive Cancer Network · 7

Pembrolizumab alone or with chemotherapy for PD-L1 positive NSCLC: A network meta-analysis of randomized trials.

2019 · Mark Doherty, Seanthel Delos Santos, et al. · Journal of Clinical Oncology · 6

Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?

2019 · Sierra Cheng, Matthew C. Cheung, et al. · Journal of the National Comprehensive Cancer Network · 4

Development of a predictive model of PSA response to a switch from prednisone to dexamethasone in metastatic castrate-resistant prostate cancer patients biochemically progressing on abiraterone.

2020 · Reeta Barua, Cameron Phillips, et al. · Journal of Clinical Oncology · 2

P1.01-16 First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials

2018 · M. Doherty, S. Delos Santos, et al. · Journal of Thoracic Oncology · 2

Prevalence of mental health outcomes and effects of sex and mood or cognitive comorbidity in older adults during the COVID-19 pandemic

2022 · Simi Jassal, Amanda Putri Rahmadian, et al. · American Journal of Geriatric Psychiatry · 1

Reassessing the net health benefit (NHB) of FDA approved cancer drugs with evolution of evidence using the American Society of Clinical Oncology Value Framework (ASCO-VF).

2020 · Seanthel Delos Santos, Noah Witzke, et al. · Journal of Clinical Oncology · 1

Immunotherapy (IO) versus non-IO for oncology drugs: Comparing survival benefits (SB) using restricted mean survival time.

2018 · Amanda Putri Rahmadian, Seanthel Delos Santos, et al. · Journal of Clinical Oncology · 1

The impact of mental health outcomes on cognition during the COVID‐19 pandemic in older adults with remitted depression, mild cognitive impairment, or normal cognition

2023 · Simi Jassal, Amanda Putri Rahmadian, et al. · Alzheimer s & Dementia

The Impact of the COVID-19 Pandemic on the Mental Health of Older Adults

2022 · Amanda Putri Rahmadian, Simi Jassal, et al. · American Journal of Geriatric Psychiatry

A network meta-analysis of adjuvant systemic therapy in resected pancreatic cancer.

2019 · Jorge Chaves Porras, Kaitlyn Perry, et al. · Journal of Clinical Oncology

Works count: 17

Citation count: 149

H-index: 6

I10-index: 5